Eton Pharmaceuticals delivered a standout Q1 2025, driven by 76% growth in product sales and newly added licensing revenue. Despite a net loss on a GAAP basis, the company posted positive non-GAAP earnings and expects continued growth from product launches and development milestones.
Total revenue rose to $17.3 million, up 117% year-over-year.
Product sales and royalties reached $14 million, up 76% YoY.
Non-GAAP EPS was $0.07 compared to $0.00 a year ago.
Cash position increased to $17.4 million with positive operating cash flow.
Eton anticipates further growth in 2025 with additional product launches and regulatory milestones expected.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance